Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Mycenax Biotech.

    Client Virtual Booth

    MYCENAX BIOTECH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Mycenax Biotech
    Taiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    4F, No. 50-7, Keyan Road, Jhunan, Miaoli 35053, Taiwan
    Telephone
    Telephone
    +886-37-586-988
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.mycenax.com.tw/en
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Richter and Mycenax Entered into an Asset Purchase Agreement of Biosimilar Tocilizumab

    Details:

    Richter receives worldwide rights to develop, manufacture and commercialise the biosimilar tocilizumab for the treatment of rheumatoid arthritis.


    Lead Product(s): Tocilizumab

    Therapeutic Area: Immunology Product Name: Undisclosed

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Gedeon Richter

    Deal Size: $19.5 million Upfront Cash: $3.0 million

    Deal Type: Agreement April 29, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Hummingbird Bioscience Announces Agreement with Mycenax Biotech for Production of Anti-VISTA Antibody

    Details:

    Pre-clinical studies have shown that HMBD-002 can strongly inhibit tumor growth, both as a monotherapy and even more potently when combined with anti-PD(L)1 treatment.


    Lead Product(s): HMBD-002

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Hummingbird Bioscience

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement February 20, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search